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The coronavirus pandemic has had a huge impact on public health with over 165 million
people infected, 3.4 million deaths and a hugely deleterious effect on most economies.
While vaccination effectively protects against the disease it is likely that viruses will
evolve that can replicate in hosts immunised with the present vaccines. Thus, there is a
great unmet need for effective antivirals that can block the development of serious
disease in infected patients. The seven papers published in this issue of the Biochemical
Journal address this need by expressing and purifying components required for viral repli-
cation, developing biochemical assays for these components and using the assays to
screen a library of pre-existing pharmaceuticals for drugs that inhibited the target in vitro
and inhibited viral replication in cell culture. The candidate drugs obtained are potential
antivirals that may protect against SARS-CoV-2 infection. While not all the antiviral candi-
dates will make it through to the clinic, they will be useful tool compounds and can act
as the starting point for further drug discovery programmes.
Commentary
The public health and economic impact of the severe acute respiratory syndrome coronavirus type 2
(SARS-CoV-2) pandemic has been enormous. As of 21st May 2021, there were over 165 million con-
firmed cases, 3.4 million deaths and many millions left with long-term illness. Aside from public
health measures to reduce transmission, 1.6 billion vaccine doses have been administered (statistics
from The John Hopkins University Centre for Systems Science and Engineering) and in countries
where vaccination rates are high, this appears to be stemming the tide of deaths and serious illness
resulting from infection. However, it is clear that rapid mutation of the virus in areas where infection
rates are high will lead to the emergence of viral variants that are no longer controlled by the existing
vaccines. Until large scale production of vaccines that neutralise the new variants comes on stream
there will be a gap in protection when there will be a requirement for antiviral compounds that ameli-
orate the consequences of infection. To date, the only antiviral used to treat patients infected with
SARS-CoV-2 is the nucleoside analogue remdesivir that inhibits the viral RNA dependent RNA poly-
merase (RdRp). Originally developed to treat Ebola infection it has emergency use authorisation for
the treatment of SARS-CoV-2 infection and is being widely tested in a clinical setting. The search for
antiviral compounds is being conducted on a global scale in academic, biotech and big pharma labora-
tories and it is to this end that a co-ordinated effort led by the biochemist John Diffley of the Francis
Crick Institute was established to search for existing drugs that would suppress replication of
SARS-CoV-2. Teams were assembled from within the Francis Crick Institute, the University of
Dundee and University College, London that would each be responsible for identifying a component
of the SARS-CoV-2 replication machinery, purifying the protein and developing assays to assess the
biochemical activity. Once this had been accomplished high-throughput assays were developed and
used to screen a custom compound library of 5000 previously characterised pharmaceuticals. The
advantage of repurposing drugs developed for other targets is the dramatically reduced time from
testing to the clinic. Approved or investigational drugs will have accumulated considerable data on
drug chemistry, pharmacology and toxicology in human patients. This would facilitate rapid passage
through clinical trials and regulatory procedures. Once candidate compounds were identified in the
screen they were then tested for their ability to inhibit viral replication in tissue culture using a plaque
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assay for infectivity. Compounds that inhibited viral replication without deleterious effects on uninfected cells
were selected as candidate antivirals. The seven papers describing these results are published in this addition of
the Biochemical Journal [1–7].
SARS-CoV-2 is an enveloped virus and contains a large (30 kb) positive-sense, single-stranded RNA
genome. These viruses gain entry to their target cells by virtue of their Spike proteins that decorate the viral
membrane and engage the angiotensin-converting enzyme 2 (ACE2) as a receptor to gain access to the cell.
The large viral mRNA is capped at its 50 end and polyA modified at its 30 end and as it is positive sense can be
directly translated by cellular ribosomes. Within the genome are 14 open reading frames (ORFs) that encode
the non-structural proteins (nsp) in two large ORFs that cover the 50 two-thirds of the genome and 12 smaller
ORFs in the 30 third of the genome that encode structural and accessory proteins translated from sub-genomic
RNAs. The two large ORFs, ORF1a and ORF1b are translated into polyprotein pp1a and polyprotein pp1ab
that is a C-terminally extended form of pp1a generated as a consequence of a -1 ribosomal frameshift. These
polyproteins are cleaved into 16 nsps by two viral proteases that excise themselves from pp1a (Figure 1a). Nsp5
is a chymotrypsin-like protease (also known as 3CLpro or Main protease Mpro) while the papain-like protease
(PLpro) is located in nsp3. The remaining 14 nsps carry out viral genome replication, transcription and mRNA
modification in addition to manipulating the host cell environment to facilitate viral replication. The first stage
in genome replication is the generation of the complementary negative-sense RNA or anti-genome that can
serve as a template for the synthesis of new genomes and for the transcription of viral mRNAs. Both of these
functions are carried out by the viral RdRp or nsp12, the catalytic core of the replication–transcription complex
(RTC) (Figure 1b). This complex is embedded in membranous structures that are hijacked from the endoplas-
mic reticulum and serve as factories for viral replication. Based on homologous proteins in other coronaviruses,
it is thought that the SARS-CoV-2 RTC is anchored on the membrane by transmembrane domains located in
nsps 3, 4 and 6. Many of the nsps, the nucleocapsid protein and many host proteins are recruited into the
RTC. Key activities of the RTC are the synthesis and capping of the viral RNAs. Capping is mediated by a sub-
complex of nsps 10, 13, 14 and 16 while RNA synthesis is mediated by nsps 7, 8, 10, 12, 13 and 14 (Figure 1b).
At the core of the synthesis, the complex is the RdRp (nsp12), its processivity factors nsp7 and 8 and the RNA
helicase activity of nsp13. With such a large genome the virus requires a proofreading exonuclease (nsp14) to
remove mispaired bases incorporated by the error-prone RdRp. Capping of viral RNA requires the concerted
Figure 1. Coronavirus non-structural proteins (nsps).
(A) The N-terminal region of the polyprotein showing the two viral proteases (blue) with green arrows indicating the sites of
cleavage mediated by the nsp3 papain-like protease (PLpro) and sites of cleavage of the nsp5 chymotrypsin-like protease (also
known as 3CLpro or Main protease Mpro) in red. (B) The capping complex and replication transcription complex with the
associated uridine specific endoribonuclease nsp15. Components studied in the drug discovery studies [1–7] indicated in blue.
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action of nsp13, an unknown GTPase, the N7 methyltransferase nsp14 and the 20-O-methyltransferase nsp16
with its nsp10 cofactor [8,9]. Viral RNA is capped not only to ensure efficient translation but also to stop
pattern recognition receptors (PRRs) from seeing uncapped mRNA as a pathogen associated molecular pattern
(PAMP) and triggering an innate immune response that would block viral replication. Likewise, it is thought
that the uridine specific nsp15 endoribonuclease associates with the RTC and removes polyU from the 50end of
negative-strand RNA, which would otherwise trigger an interferon response.
The strategy take by the team was to target the two viral proteases required for excision of the nsps from the
initially translated polyproteins, the RNA synthesis machinery, components of the capping complex and the
nsp15 endoribonuclease (Figure 1b). All these proteins are essential genes, are mutationally constrained and
can be assayed biochemically. They thus represent excellent targets for antiviral drugs. The product of nsp14 is
a bifunctional enzyme with an N-terminal 30-50 exoribonuclease (ExoN) domain and a C-terminal
S-adenosylmethionine-dependent N7 methyltransferase domain. As nsp14 is associated with both the replica-
tion transcription and the capping complexes this is consistent with the involvement of the ExoN activity being
involved in proofreading during replication/transcription and the N7 methyltransferase activity being involved
in capping. While it can be advantageous for viruses to accumulate mutations to escape from immune surveil-
lance and become resistant to drugs, the accumulation of many mutations in a large genome could lead to loss
of fitness. Drugs against the proofreading activity could be very useful as it is this very activity that can remove
nucleotide analogue chain terminators after they have been incorporated into the growing RNA chain, thus
reducing the effectiveness of these antiviral drugs. It was demonstrated [1] that Patulin, a lactone mycotoxin
that had previously been tested against the common cold, inhibited the ExoN activity of nsp14 and reduced
viral replication, although some toxicity was observed. Aurintricarboxylic acid, a known nuclease inhibitor,
appeared to have specificity for Nsp14 and also inhibited viral replication. The other activity of Nsp14 is a
guanine N7 methyltransferase involved in the capping of viral RNAs. It was shown [2] that many known drugs
inhibited this activity: Lomeguatrib, an inhibitor of O6-methyl guanine DNA methyltransferase that enhances
the effect of DNA alkylating agents in cancer treatment; Trifluperidol, used in the treatment of psychoses;
IF-03882845 a non-steroidal mineralocorticoid antagonist used to treat diabetic nephropathy. While all inhib-
ited viral replication and had synergistic interactions with remdesivir the severe side effects associated with
Trifluperidol may limit its use as a single agent. A series of compounds related to suramin were shown to
inhibit the RdRp encoded by nsp12 in complex with its processivity factors nsps 7 and 8 [3]. Suramin was
developed over 100 years ago by Bayer for the treatment of river blindness and sleeping sickness and is known
to inhibit multiple viruses. GSK-650394 also inhibited the RdRp and blocked SARS-CoV-2 replication. Its
intended target is serum and glucocorticoid-activated kinase (SGK1 and 2) but it also inhibits influenza virus
replication. Involved in both replication/transcription and capping the Nsp13 RNA helicase was shown to be
inhibited by FPA-124, a cell-permeable Akt inhibitor and like the RdRp was also inhibited by several suramin
related compounds [4]. Although both inhibited viral replication in cell culture experiments it remains to be
established if inhibition is via Nsp13. The Nsp15 uridine specific endoribonuclease was shown to be inhibited
by NSC95397 in vitro but it did not appear to exert any inhibitory effect in vivo [5]. Protease inhibitors are
effective antivirals and have been licenced for the treatment of human immunodeficiency virus (HIV) and
hepatitis C virus [10]. The two SARS-CoV-2 proteases (Figure 1a) were thus attractive targets for the develop-
ment of antiviral drugs. The main protease Nsp5 was inhibited by Calpain inhibitor 1 which also reduced viral
infectivity in cell culture. Peptidyl fluoromethylketones that mimicked the peptide cleavage site in the virus
polyprotein were highly specific and potent inhibitors in vitro but less so in vivo [6]. They represent excellent
starting points for further drug development. PLpro the papain-like protease encoded in Nsp3 was inhibited by
Dihydrotanshinone a natural compound from Salvia miltiorrhiza used in Chinese medicine. It inhibits the
cleavage of viral peptides and inhibits isopeptidase activity against ubiquitin and ISG15. In cell culture, it
blocks viral replication with no observable toxicity [7].
It is important to have multiple drug candidates. One reason for this is the attritional nature of any drug dis-
covery programme. Many drugs that are effective in a tissue culture setting will fall by the wayside during
animal testing and clinical trials. The other reason is that drugs against multiple targets may be necessary to
counteract the development of drug-resistant mutants. The simultaneous delivery of multiple drugs is the strat-
egy that has been used successfully to treat acquired immune deficiency syndrome (AIDS) caused by HIV.
Given the rate at which mutations accumulate in the HIV genome, the administration of a single drug rapidly
results in the development of resistance. However, the administration of a cocktail of three different drugs
hitting different targets makes it very difficult for the virus to simultaneously acquire resistance to all three
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2401
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drugs. As SARS-CoV-2 replication/transcription is associated with a proofreading activity and causes an acute
infection compared with the persistent HIV infection and it may be that SARS-CoV-2 would accumulate less
mutations than HIV. However, it would certainly be desirable to have an arsenal of drugs inhibiting different
targets to provide clinicians with a range of options when treating SARS-CoV-2 infected patients.
The next stage for these drug candidates is that they will need to be tested to determine their ability to block
SARS-CoV-2 infection and pathogenicity in vivo. Initially, this could be done in transgenic mice expressing
human ACE2. Upon intranasal inoculation with SARS-CoV-2 these mice develop a pulmonary infection that
appears to mimic the pathological changes seen in patients infected with SARS-CoV-2 [11]. If the candidate
drugs are successful in this setting they would need to be tested in non-human primates before moving on to
clinical trials.
While many of the drug candidates with antiviral activity may not make it through to the clinic they can be
very useful tool compounds for investigators studying SARS-CoV-2 replication. The ability to block the activity
of non-structural components of the virus provides the researcher with the means to dissect the viral replication
cycle. These drug candidates can also act as the starting point for further drug discovery programmes. Many
the nsps targeted in the accompanying papers have already had their 3D structures determined by X-ray crys-
tallography or cryoelectron microscopy [12–21]. Determination of the drug nsp complexes would allow the
drug candidates to be optimised for binding specificity and affinity. This study also provides an excellent
resource for other investigators working in this area to obtain expression constructs and assay details.
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